UCLA to host 11th Annual Brain Tumor Conference
April 15th & 16th 2011
FREE REGISTRATION FOR PATIENTS,
PHYSICIANS AND CARE GIVERS

Art of the Brain Annual Gala
The Gleeful Art of Sportsmanship

Phase II Study of ImClone IMC-3G3
and IMC-1121B for Patients With Recurrent Diagnosed Glioblastoma Multiforme

Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

UCLA JOURNAL ARTICLES AT:
NEUROONCOLOGY.UCLA.EDU

NEW STRATEGIES IN THE MOLECULAR TARGETING OF GliOBLASTOMA: HOW DO YOU HIT A MOVING TARGET?

CORRELATION OF 6-18F-FURO-1-DOPA PET UPTAKE WITH PROLIFERATION AND TUMOR GRADE IN NEWLY DIAGNOSED AND RECURRENT GliOMAS.

A PHASE I TRIAL OF TIPIFARNIB WITH RADIATION THERAPY, WITH AND WITHOUT TEMOZOLOMIDE, FOR PATIENTS WITH NEWLY DIAGNOSED GliOBLASTOMA.
Phase II Study of ImClone IMC-3G3 and IMC-1121B for Patients With Recurrent Diagnosed Glioblastoma Multiforme

The UCLA Neuro-Oncology Program is set to begin a phase II clinical trial, sponsored by ImClone LLC, for patients with recurrent glioblastoma multiforme (GBM). The trial will study the safety and effectiveness of two experimental drugs, IMC-3G3 and IMC-1121B, as well as assess the disease progression-free survival rate in the treatment of patients with recurrent GBM.

GBM tumors are the most aggressive form of gliomas. They have enhanced expression of proangiogenic proteins and receptors that allows tumor cell proliferation, tumor migration, progression and increased risk of tumor recurrence. Specifically, VEGFR2 and PDGFR α are two of these mediators of tumor growth that are being studied and targeted through this clinical trial. Vascular endothelial growth factor (VEGF) and its receptor, VEGFR-2, play predominant roles in angiogenesis of malignant gliomas. VEGF facilitates vascular endothelial tumor growth and cell proliferation by recruiting vasculature from surrounding blood vessels to promote pathways to tumor growth. Platelet Derived Growth Factor (PDGF) and its receptor, PDGFR α, are members of the VEGF family that have been found in previous studies to play a unique role in regulating tumor formation.

ImClone LLC has developed IMC-3G3 and IMC-1121B hoping to prevent angiogenesis and the progression of disease. Both agents are monoclonal antibodies that bind to PDGFR α and VEGFR-2, respectively, to inhibit tumor growth. Pre-clinical studies have shown that these antibodies bind to the receptors with high affinity. Specifically, IMC-1121B impairs activation of the VEGF pathway by targeting VEGFR2 and blocking the interactions of VEGF and VEGFR2. Meanwhile, IMC-3G3 binds to PDGFR α to block PDGF from binding to other cells.

While many studies have focused on anti-angiogenesis through monotherapy, finding a multi-targeted approach would be optimal due to the complexities of tumor development. Although this study will focus on the use of IMC-1121B and IMC-3G3 separately, if results of this study show success in inhibiting tumor growth, both therapeutic agents may be considered for combination therapy for maximal treatment of GBM.

The IMC-3G3 and IMC-1121B clinical trial is a multi-site study being offered at UCLA with plans to enroll 80 patients nationwide through the American Brain Tumor Consortium. To be eligible for enrollment, patients must be at least 18 years of age and have a recurrent GBM tumor, status post radiation therapy and temozolomide chemotherapy. Prior surgical resection is not necessary. Patients who were previously diagnosed with a low grade glioma and later had tumor recurrence pathologically diagnosed as a GBM are also eligible. Measurable tumor progression via MRI is required, as well as meeting certain laboratory criteria. Patients must also have a Karnofsky Performance Status greater than or equal to 60%.

Once enrolled, patients will be assigned to either the IMC-3G3 group or IMC-1121B group. Baseline MRI scans will be done within 2 weeks of starting the treatment. Both drugs will be administered via intravenous (IV) infusion every
Choosing to participate in a clinical trial is an important personal decision. It is often helpful to talk to a physician, family members, or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials.

For more information about any of the UCLA Neuro-Oncology Program’s clinical trials listed, please contact Emese Filka, Clinical Trials Coordinator, at (310) 794-3521.

**UCLA Neuro-Oncology Clinical Trials**

Choosing to participate in a clinical trial is an important personal decision. It is often helpful to talk to a physician, family members, or friends about deciding to join a trial. After identifying some trial options, the next step is to contact the study research staff and ask questions about specific trials.

For more information about any of the UCLA Neuro-Oncology Program’s clinical trials listed, please contact Emese Filka, Clinical Trials Coordinator, at (310) 794-3521.

<table>
<thead>
<tr>
<th>Study Code</th>
<th>Study Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVF4535s</td>
<td>Phase II Study of Bevacizumab and Temozolomide in Elderly Patients with Newly Diagnosed Glioblastoma</td>
</tr>
<tr>
<td>GDC-0449</td>
<td>Biomarker and Phase II Study of GDC-0449 in Patients with Recurrent Glioblastoma Multiforme</td>
</tr>
<tr>
<td>IMC-3G3 and IMC-1121B</td>
<td>Open Label, Phase II Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients with Recurrent Glioblastoma Multiforme</td>
</tr>
<tr>
<td>XL184-201</td>
<td>Phase II Study of XL184 in Subjects with Progressive or Recurrent Glioblastoma Multiforme in First of Second Relapse</td>
</tr>
<tr>
<td>XL765 and Temozolomide</td>
<td>Phase I Dose-Escalation Study of XL765 in Combination with Temozolomide in Subjects with Malignant Gliomas</td>
</tr>
<tr>
<td>Toca 511</td>
<td>Phase I Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients with Recurrent Glioblastoma Multiforme</td>
</tr>
<tr>
<td>Vorinostat and Temozolomide</td>
<td>Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination with Temozolomide in Patients with Malignant Gliomas</td>
</tr>
<tr>
<td>VEGF Trap / XRT / TMZ</td>
<td>Phase I Trial of Aflibercept (VEGF Trap) with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients with Malignant Glioma</td>
</tr>
<tr>
<td>XL765 and XL147</td>
<td>An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects with Recurrent Glioblastoma Who are Candidates for Surgical Resection</td>
</tr>
<tr>
<td>XL184</td>
<td>Phase I Dose Finding Study of the Safety and Pharmacokinetics of XL184 Administered Orally in Combination with Temozolomide and Radiation Therapy in the First Line Treatment of Subjects with Malignant Gliomas</td>
</tr>
</tbody>
</table>

Two weeks. Each treatment cycle is 14 days. Patients will also go through a physical and mental exam to monitor the effect of the study treatment. Routine blood tests and urinalysis will also be performed before each infusion. MRIs will be done every 8 weeks to monitor the response of the tumor to the experimental drug.

In addition, the first 10 patients enrolled in each study group will have blood drawn one hour after the end of infusion to monitor levels of the experimental agents in the study subject’s system and to analyze for biological markers. Also, the first 8 patients enrolled in each group will have additional special research MRIs done on Days, 1, 2, 26, 56, and then every 56 days while on study.

For more information about this study, please contact Emese Filka, clinical trials coordinator for the UCLA Neuro-Oncology Program at (310) 794-3521.
Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme


In the Jan. 10, 2011 edition of the Journal of Clinical Oncology, the article entitled "Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme" was published.

Dr. Albert Lai, Assistant Professor in the UCLA Dept of Neurology and attending physician with UCLA Neuro-Oncology was the lead author and Dr. Timothy F. Cloughesy, Clinical Professor in the UCLA Dept of Neurology and Director of the UCLA Neuro-Oncology Program, was the senior author.

This article was highly anticipated as it was one of the first studies to investigate whether using bevacizumab (BV) as upfront treatment was beneficial to using it as recurrent treatment. Patients were enrolled in the trial at UCLA, Kaiser Northern California, and Kaiser Southern California.

In addition to detailing the outcomes of patients enrolled in the trial, a University of California Los Angeles/Kaiser Permanente Los Angeles (KPLA) control cohort of newly diagnosed patients treated with first-line radiation therapy (RT) and temozolomide (TMZ) who had mostly received BV at recurrence was derived for comparison.

The conclusion was that, while the early use of bevacizumab was tolerable, there appeared to be no survival benefit compared to the use of bevacizumab at recurrence. Ongoing, multi-center randomized phase III trials are underway to examine this question definitively.

At the recent 2010 Annual Meeting of the Society for Neuro-Oncology held in November 2010, Dr. Lai presented a study entitled “IDH1 Mutant Glioblastoma: Evidence for Sequenced Molecular Evolution from a Developmentally Restricted Cell of Origin.” This represented a collaborative effort with Dr. Heidi Phillips and her colleagues at Genentech. In this study which examined tumor tissue, imaging, and clinical outcomes for over 600 glioblastoma (GBM) patients, the authors conclude that IDH1R132MUT GBMs arise via a sequenced series of molecular alterations from a restricted progenitor cell type involved in late frontal lobe maturation. These findings have widespread implications in our understanding of how some glioblastomas arise and how they may be attacked.

Both studies illustrate how ‘every patient is part of the cure,’ and would not have been possible without the willingness of so many of our patients to consent to participate in the Study of Central Nervous System Tumors: A Database for Patients with Central Nervous System Tumors.
UCLA Neuro-Oncology to host 11th Annual Brain Tumor Conference April 15th-16th, 2011

Join brain cancer survivors, family members, friends and health care professionals at the 11th Annual Brain Tumor Conference, hosted by the UCLA Neuro-Oncology Program. This FREE conference will offer participants the opportunity to hear leading healthcare professionals speak about the latest treatments for brain tumors. Through this conference, the Neuro-Oncology Program promotes the sharing of information and experience between brain tumor survivors, their families, friends and health care professionals.

### Event Details

<table>
<thead>
<tr>
<th>Date</th>
<th>April 15th &amp; 16th 8am - 5pm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location</td>
<td>UCLA De Neve Plaza 351 Charles E. Young Drive West 2nd Floor Los Angeles, CA 90095</td>
</tr>
<tr>
<td>Event Cost</td>
<td>FREE</td>
</tr>
</tbody>
</table>

**Pre-registration is required. Early registration is encouraged as conference space and materials are limited.**

**CME/CE Units are NOT offered**

### HOW TO REGISTER

**Online:** Visit www.neurooncology.ucla.edu and fill out the secure registration form by April 12, 2011.

**Mail:** Fill out the enclosed registration form and return by April 9, 2011 to: UCLA Neuro-Oncology 710 Westwood Plaza Reed Bldg RM 1-230 Los Angeles, CA 90095

**Fax:** Or fax the enclosed registration form to (310) 825-0644 by April 12, 2011

### HOTEL ACCOMMODATIONS

There are several surrounding hotels available for accommodation during the conference.

- **UCLA Guest House** (310) 825-2923
- **Hilgard House** (310) 208-3945
- **W Hotel - Westwood** (310) 208-8765
- **The Claremont Hotel** (310) 208-5957
- **Angeleno Hotel** (310) 476-6411

FOR FRIDAY PARKING: From Westwood Plaza, turn left on Structure 8 Driveway, proceeding up the ramp to the top level (Level 4) of Parking Structure 8. Purchase a parking permit from the attendant at the parking entrance (from 7am to 1pm). After 1pm, please purchase a permit at the Parking Kiosk located on Westwood Plaza prior to proceeding to Structure 8 Driveway. Park in any UNRESTRICTED space. Daily parking permits are $10 and daily disabled parking permits are $3 per day. From Lot 8, a transportation shuttle will be provided for transport to De Neve Plaza Commons. Pick up location in Lot 8 is on the top level of the parking structure. Please locate shuttle/shuttle sign for pick up location. From the shuttle drop-off point at De Neve Plaza, proceed inside De Neve Plaza Commons and take elevator to the 2nd Floor.

FOR SATURDAY PARKING: From Westwood Plaza, turn left on Strathmore Drive. Then turn right onto Charles E. Young Drive West. Make a left turn at the first driveway on your left-hand side and follow the road leading to Parking Structure DD. Purchase a parking permit from the attendant at the parking lot gate from 7am to 1pm. After 1pm, please purchase permit from the Parking Information Kiosk at Strathmore & Westwood Blvd., prior to proceeding to Parking Structure DD. Park in any UNRESTRICTED space. Daily parking permits are $10 and daily disabled parking permits are $3 per day.

Visit www.neurooncology.ucla.edu for detailed map and updated conference schedule.
UCLA 11th Annual Brain Tumor Conference
Schedule of Events

FRIDAY, APRIL 15, 2011: 
GENERAL SESSIONS

8:00 am  Registration & Continental Breakfast

9:00 am  Welcome & Overview of Brain Tumors
Timothy Cloughesy MD
Program Director – UCLA Neuro-Oncology

10:00 am  Neuro-Surgery Techniques &
Image-Guided Surgery
Linda Liau MD, PhD
Professor, UCLA Dept. of Neurosurgery

11:00 am  Stereotactic Radiotherapy &
Radiation Therapy
Antonio DeSalles MD
Professor, UCLA Dept. of Neurosurgery

12:00 pm  LUNCH

1:00 pm  Chemotherapy
Albert Lai MD; PhD
Assistant Professor, UCLA Dept of Neurology

1:45 pm  Understanding Neuropathology
William Yong MD
Professor, UCLA Pathology & Lab Medicine

2:45 pm  Experimental Therapies:
Clinical Trials & Biological Agents
Leia Nghiemphu MD
Assistant Professor, UCLA Dept of Neurology

3:30 pm  Brain Tumor Tissue Banking
William Young MD;
Professor, UCLA Pathology & Lab Medicine

4:00 pm  Diagnostic Tools (Imaging)
Dr. Whitney Pope
Associate Professor, UCLA Radiological Science

SATURDAY, APRIL 16, 2011: 
BREAKOUT SESSIONS

8:00 am  Registration & Continental Breakfast

9:00 am  SESSION 1 
A. Neuro-Psychology and Brain Tumors
Patricia Walshau, PhD, UCLA Dept of Psy & Biobeh
B. Legal Issues I: Employment & Benefits
Shawn Kravic, Esq, Cancer Legal Resource Center
C. Complementary Medicine Approaches
Mary Hardy MD, UCLA Simms / Mann Center
D. Seizure Management
Naveed Wagle, MD & Jose Carrillo, MD

10:00 am  SESSION 2 
A. Symptom Management
Nanette Fong NP, UCLA Neuro-Oncology Program
B. Palliative Care and End of Life Issues
Dr. Leia Nghiemphu & Cheryl Abe, LCSW
C. Integrating Psychosocial Support Into Treatment -
Richard Hart, JD, MA, Cancer Support Community

11:00 am  SESSION 3 
A. Nutrition for Brain Tumor Patients
Carolyn Katzrin - Certified Nutrition Specialist
B. Tumor Type: Brain Metastasis
Timothy Cloughesy M.D
C. Helping Children When A Parent Has A Brain Tumor
Kati Kern, LCSW
D. Mindfulness Meditation
Lisa Kring, LCSW, UCLA Simms/Mann Center

11:45 pm  LUNCH

12:45 pm  SESSION 4 
A. Understanding Clinical Trials
Stacey Green NP, UCLA Neuro-Oncology Program
B. Understanding Language Impairments
Dr. Susan Bookheimer, UCLA Dept of Psychiatry
C. Understanding the Family Experience
Cheryl Abe LCSW, UCLA Oncology Center
Pam Hoff LCSW, UCLA Dept of Radiation Oncology
D. Legal Issues: Navigating Health Insurance
Shawn Kravic, Esq, Cancer Legal Resource Center

1:45 pm  SESSION 5 
A. Tumor Type: Glioblastoma & Anaplastic Astrocytoma
Dr. Timothy Cloughesy
B. Tumor Type: Oligodendroglioma & Low Grade Tumors
Dr. Albert Lai
C. Tumor Type: Meningioma
Dr. Richard Green, Dir. - Kaiser LA Neuro-Oncology
D. Tumor Type: Rare Tumors
Dr. Leia Nghiemphu, UCLA Neuro-Oncology

Consultation Sessions
Participants will have the opportunity to make appointments
for free 15-minute consult sessions with a participating physi-
cian regarding on-going care, neurosurgery, radiation,
symptom management, etc.
Sign-ups are available only on the day of event.
Space is limited arrive early to reserve an appointment time.
# UCLA CONFERENCE REGISTRATION FORM

Please complete this form and return to: UCLA Brain Tumor Conference C/O Luzianne Dugenia Fernandez 710 Westwood Plaza, Reed Building #1230 Los Angeles, CA 90095 If registering by fax, do NOT send form by mail. Fax: 310.825.0644 Phone: 310.206.3610 Online Registration: www.neurooncology.ucla.edu Registration deadline by fax or online is April 12th Mailed forms must be postmarked by April 9th

If registering family member(s) or companion(s), please complete a separate Registration Form for each attendee. Send all forms together to the address listed above.

<table>
<thead>
<tr>
<th>FIRST NAME</th>
<th>LAST NAME</th>
<th>DEGREE</th>
<th>TITLE</th>
<th>ORGANIZATION</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ADDRESS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CITY</th>
<th>STATE</th>
<th>ZIP CODE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PHONE</th>
<th>EMAIL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**PLEASE INDICATE WHICH WORKSHOP(S) YOU PLAN TO ATTEND FOR EACH DAY**

### FRIDAY, APRIL 15TH, 2011: GENERAL SESSIONS

- _____ Overview of Brain Tumors
- _____ Brain Tumor Tissue Banking
- _____ Neurosurgery Techniques
- _____ Radiation Treatments
- _____ Understanding Neuropathology
- _____ Clinical Trials & Biological Agents
- _____ Chemotherapy

### SATURDAY, APRIL 16TH, 2011: BREAKOUT SESSIONS (Please choose ONE from each session)

**SESSION 1: 9:00 -9:45am**

- _____ A. Neuro-Psychology
- _____ B. Employment & Benefits
- _____ C. Complementary Medicine
- _____ D. Seizure Management

**SESSION 2: 10:00-10:45am**

- _____ A. Symptom Management
- _____ B. End of Life Issues
- _____ C. Psychosocial Support

**SESSION 3: 11:00-11:45am**

- _____ A. Nutrition
- _____ B. Brain Metastasis
- _____ C. Helping Children When A Parent Has A Brain Tumor
- _____ D. Mindfulness Meditation

**SESSION 4: 12:45-1:30pm**

- _____ A. Clinical Trials
- _____ B. Language Impairments
- _____ C. Family Experience
- _____ D. Legal Issues: Navigating Health Insurance

**SESSION 5: 1:45-2:30pm**

- _____ A. Tumor Type: GBM/AA
- _____ B. Tumor Type: Meningiomas
- _____ C. Tumor Type: Low Grade & Oligodendrogliomas
- _____ D. Tumor Type: Rare Tumors

Do you require a vegetarian meal? Yes No
Do you require special assistance? Yes No Please specify:
Currently receiving treatment at UCLA? Yes No Type of brain tumor:
How did you hear about this conference?
Art of the Brain 11th Annual Gala: “The Gleeful Art of Sportsmanship”

Art of the Brain, a non-profit organization under the auspices of The UCLA Foundation, held its eleventh annual fundraising gala on Saturday, October 2, 2010 to honor brain cancer survivors and supporters and raise funds for brain cancer research headed by Dr. Timothy Cloughesy at the UCLA Neuro-Oncology Program.

The 2010 event celebrated “The Gleeful Art of Sportsmanship” through art and song; and also honored individuals who have made and continue to make strides in research and philanthropy. Over 300 supporters attended the event, which included both a reception and program.

The reception offered an art exhibit, raffle, and food stations. Attendees were treated to feast of culinary magic, fine wines and beverages from local establishments that included Barney’s Beanery, Buddha’s Belly, Buttermilk Bakery, Coffee Cup Café, LA Gourmet, Laraine Wines, Adelaida Cellars, Niko Niko, Pure Cheesecakes, Viktor Benes, Stan’s Donuts, and Peets Coffee.

The evening’s theme and the program, which was produced by Dari Mackenzie and Annie Gerhart, were inspired by the people who have brought glee to those experiencing hardships that come with brain cancer: a loved one, a family member, a friend. To celebrate them, the Vocal Ensemble group from John Burroughs High School Vocal Music Association, who was the inspiration for the hit show “Glee,” performed spirited songs. The Vocal Ensemble is a select group of members who are part of JBHS’s award-winning show choir “Powerhouse.” They performed acapella versions of popular songs and brought a lively and gleeful energy to the event.

Jason Barry, a reporter for the Phoenix CBS-affiliate and whose father was a brain cancer patient of Dr. Cloughesy’s, was master of ceremony for the program.

Also featured in the program was the presentation of the Judi Kaufman Founders Responsibility Award. Mac Balch and Jason Lopata were this year’s honorees. This award recognizes those who have contributed to brain cancer research through philanthropy. Balch and Lopata are both teens who have been affected by brain cancer through a member of each of their families. Balch lost his older brother to brain cancer just two and a half years ago, while Lopata had lost his grandfather many years ago while he was a very young boy. Both have been inspired to do more...
to help brain cancer research progress so that others can be spared of watching a loved one suffer from this disease. Thus, the creation of the new Youth Partnership with pledges from both to help raise awareness among the younger generation and fundraise for a cure.

The Johnny Mercer Foundation Research Award was also presented at the event to Whitney Pope, M.D., Ph.D. for his commitment to brain cancer research. His research interests are determining the relationship between imaging and gene expression in Glioblastoma Multiforme (GBM) tumors; using advanced imaging analysis to predict survival in GBM patients with anti-angiogenic drugs; analyzing patterns of brain tumor recurrence following anti-angiogenic drug therapy; and developing ways to determine response to drugs at the earliest time point possible. Dr. Pope is committed to brain cancer research in hopes of ultimately finding a cure.

Since the organization’s inception in 2000, Art of the Brain has raised more than $3.7 million, with over $330,000 raised in 2010. Money raised through Art of the Brain has provided funding for the training of several physician-scientists who have developed research projects aimed at eradicating brain cancer, and also continues to support a number of ground-breaking clinical research studies.

The 2010 Gala would not have been a success without the support of its sponsors.

SPORTSMANSHIP SPONSORS: The Johnny Mercer Foundation, The Lopata Family

TEAM SPONSORS: Richard Dean Anderson, City National Bank, Joan and Gerald Doren, Judi and Roy Kaufman, The Beryl Companies

PLAYER SPONSORS: Joyce and William Bromiley, Kathryn Browning & Browning Mazda, Marlene and David Capell, Carsey Family Foundation, Clint and Dina Eastwood, Gang Tyre Ramer & Brown, Bruce and Madeline Ramer, Sue Ann and Richard Masson, Virginia and Bob Newhart, Ann Ramer, Louis Rosenmayer, The Shirley and Burt Harris Family Foundation, Valterra Products, Inc., Gy and Jadi Waldron, Bunny Wasser and Howard Bernstein

Art of the Brain is an organization dedicated to helping those who are affected with brain cancer through fundraising for brain cancer research at UCLA and also offering support system for those in need through their Brain Buddies.

For those who are interested in supporting Art of the Brain, either by volunteering or making a contribution, please visit the Art of the Brain website at www.artofthebrain.org or call (310) 825-5074.
4th Annual Barry Spiegelman Memorial Golf Classic in Dallas, April 12th, 2011

The Beryl Companies of Bedford, Tex. will host the 4th Annual Barry Spiegelman Memorial Golf Classic and Reception & Fundraiser in the Dallas area on April 12, 2011 in support of brain cancer research at UCLA’s Art of the Brain program. The event is named in honor of Barry Spiegelman, co-founder of The Beryl Companies, who passed away from a brain tumor in 2005.

According to Paul Spiegelman, Barry’s brother and also a co-founder of Beryl, Barry was a patient of Dr. Tim Cloughesy, director of UCLA’s Neuro-Oncology department and the driving force behind the Art of the Brain program. “Tim was an inspiration to Barry. Not only did he provide compassionate, personal care as his physician, but he gave Barry the strength and support he needed to fight with a positive attitude,” said Spiegelman. “Tim is making a difference in people’s lives every day and we are using our fundraising efforts to remember Barry and support Tim’s efforts.”

You can help support this event in numerous ways, including sponsorships, cash donations, donations of gift items for the raffle and silent auction, or playing in the golf tournament. To sponsor, donate or register to golf, please visit www.barryspiegelmanmemorial.com or call 817-785-5029.

Caregiver Support Group

Care giving is a human act of kindness required by all family members. Those faced with caring for a loved one with a cancer diagnosis can be especially difficult. UCLA Caregiver Support Group is designed to help and encourage those facing all support challenges, and help give the mental strength to deal with all of the emotions caregivers’ experience. If you would like to attend the next meeting please call (310) 825-6134 to RSVP.

Next Meeting Dates:

- March 10, 2011
- April 14, 2011
- May 12, 2011
- June 9, 2011

Group meets at:

- UCLA Medical Center
- 200 Medical Plaza
- Level B2, Room 265
- Los Angeles, CA 90095
UCLA Memorial Fund Giving

Giving is a selfless act that could have a huge impact on the path to finding a cure for brain cancer. No matter the size of the donation, large or small, that extra push could mean a world of difference in the race to find a cure. Gifts the UCLA Neuro-Oncology Program has received in honor and memory of those who are listed below have played a role in the advancement of brain cancer research at UCLA.

If you would like more information about making a donation to the UCLA Neuro-Oncology Program or creating a memorial fund, please call (310) 206-3610.

### 2011 Memorial Funds

11th Annual Brain Tumor Conference
April 15th & 16th, 2011

Presented By:
University of California, Los Angeles; Neuro-Oncology

REGISTRATION DEADLINE
ONLINE & FAX: APRIL 12TH, 2011
MAIL-IN: APRIL 9TH, 2011

SEE INSIDE FOR DETAILS
FOR MORE INFORMATION, PLEASE CALL 310.206.3610

* THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL DONATION PROVIDED BY AMGEN & SILICONMED